The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objective was to determine the potential cost-effectivenes...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1971017 |
| _version_ | 1797673297092018176 |
|---|---|
| author | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Michael Drummond Milton C. Weinstein |
| author_facet | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Michael Drummond Milton C. Weinstein |
| author_sort | Michele A. Kohli |
| collection | DOAJ |
| description | In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objective was to determine the potential cost-effectiveness of vaccinating adults aged 65 years and above with aQIV compared with QIV-HD in the UK. A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the impact of vaccination in 10 influenza seasons. Vaccine effectiveness was based on a meta-analysis that concluded the vaccines were not significantly different. Vaccine coverage, physician visits, hospitalizations, deaths, utility losses and NHS costs were estimated using published UK sources. The list price of aQIV was £11.88 while a range of prices were tested for QIV-HD. The price of the trivalent high-dose vaccine (TIV-HD) is £20.00 but a list price for QIV-HD is not yet available. The projected differences between the vaccines in terms of clinical cases and influenza treatment costs are minimal. Our analysis demonstrates that in order to be cost-effective, the price of QIV-HD must be similar to that of aQIV and may range from £7.57 to £12.94 depending on the relative effectiveness of the vaccines. The results of the analysis were most sensitive to variation in vaccine effectiveness and the rate of hospitalization due to influenza. Given the evidence, aQIV is cost-saving unless QIV-HD is priced lower than the existing list price of TIV-HD. |
| first_indexed | 2024-03-11T21:42:29Z |
| format | Article |
| id | doaj.art-35b1566157c44197be5c7944183a51c6 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:29Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-35b1566157c44197be5c7944183a51c62023-09-26T12:43:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-11-0117114603461010.1080/21645515.2021.19710171971017The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United KingdomMichele A. Kohli0Michael Maschio1Joaquin F. Mould-Quevedo2Michael Drummond3Milton C. Weinstein4Quadrant Health Economics IncQuadrant Health Economics IncSeqirus USA IncCentre for Health Economics, University of YorkHarvard T.H. Chan School of Public HealthIn the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objective was to determine the potential cost-effectiveness of vaccinating adults aged 65 years and above with aQIV compared with QIV-HD in the UK. A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the impact of vaccination in 10 influenza seasons. Vaccine effectiveness was based on a meta-analysis that concluded the vaccines were not significantly different. Vaccine coverage, physician visits, hospitalizations, deaths, utility losses and NHS costs were estimated using published UK sources. The list price of aQIV was £11.88 while a range of prices were tested for QIV-HD. The price of the trivalent high-dose vaccine (TIV-HD) is £20.00 but a list price for QIV-HD is not yet available. The projected differences between the vaccines in terms of clinical cases and influenza treatment costs are minimal. Our analysis demonstrates that in order to be cost-effective, the price of QIV-HD must be similar to that of aQIV and may range from £7.57 to £12.94 depending on the relative effectiveness of the vaccines. The results of the analysis were most sensitive to variation in vaccine effectiveness and the rate of hospitalization due to influenza. Given the evidence, aQIV is cost-saving unless QIV-HD is priced lower than the existing list price of TIV-HD.http://dx.doi.org/10.1080/21645515.2021.1971017influenza vaccinecost-effectivenesseconomic modeling |
| spellingShingle | Michele A. Kohli Michael Maschio Joaquin F. Mould-Quevedo Michael Drummond Milton C. Weinstein The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom Human Vaccines & Immunotherapeutics influenza vaccine cost-effectiveness economic modeling |
| title | The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom |
| title_full | The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom |
| title_fullStr | The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom |
| title_full_unstemmed | The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom |
| title_short | The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom |
| title_sort | cost effectiveness of an adjuvanted quadrivalent influenza vaccine in the united kingdom |
| topic | influenza vaccine cost-effectiveness economic modeling |
| url | http://dx.doi.org/10.1080/21645515.2021.1971017 |
| work_keys_str_mv | AT micheleakohli thecosteffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT michaelmaschio thecosteffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT joaquinfmouldquevedo thecosteffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT michaeldrummond thecosteffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT miltoncweinstein thecosteffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT micheleakohli costeffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT michaelmaschio costeffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT joaquinfmouldquevedo costeffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT michaeldrummond costeffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom AT miltoncweinstein costeffectivenessofanadjuvantedquadrivalentinfluenzavaccineintheunitedkingdom |